Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03979781 · ClinicalTrials.gov registry record · Phase 2
Personalized Antiplatelet Secondary Stroke PRevenTion
A Phase 2 study, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT03979781: Completed Phase 2 study, sponsored by State University of New York - Upstate Medical University.
NCT03979781 is a Phase 2 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03979781, a Phase 2 study, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a descriptive study designed to evaluate the safety and feasibility of a precision medicine approach to antiplatelet selection for secondary stroke prevention.
Primary Outcome
ability to recruit participants and achieve platelet reactivity target using platelet function assays
Interventions
- DRUG standard of care
- DRUG tailored antiplatelet selection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2018-06-11 |
| Est. Completion | 2023-05-09 |
| Phase | Phase 2 |
What the finished NCT03979781 record still lists
NCT03979781 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 2 interventions - of which standard of care is the first listed.
NCT03979781 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03979781 about?
NCT03979781 is a clinical study titled "Personalized Antiplatelet Secondary Stroke PRevenTion". This is a descriptive study designed to evaluate the safety and feasibility of a precision medicine approach to antiplatelet selection for secondary stroke prevention.
What is the current status of trial NCT03979781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2018-06-11. Estimated completion is 2023-05-09.
What interventions are being tested in trial NCT03979781?
The interventions under investigation include: standard of care (DRUG), tailored antiplatelet selection (DRUG).
Who is sponsoring clinical trial NCT03979781?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03979781's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI